MedTrace Logo

Stress and Rest Myocardial Tomoscintigraphies Using Mono- or Double-isotope Protocol With a Semiconductor Camera

NCT02869126 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2016-08-16

No results posted yet for this study

Summary

The purpose is to demonstrate the concordance of diagnostic information obtained with:

1. a conventional examination with 2 distinct recordings on D.SPECT camera after 99mTc-sestamibi injections, the first post-stress and the second at rest, 2 to 3 hours later,

and
2. a double isotope examination with a supplementary recording after injection of a little activity of thallium-201 at rest after the first recording and before the second injection of 99mTc-sestamibi for conventional recording at rest,

in patients showing abnormalities of myocardial perfusion in stress myocardial tomoscintigraphy.

Conditions

  • Myocardial Perfusion

Interventions

PROCEDURE

Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)

* During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient * Stress conventional acquisition with D.SPECT camera 20 min after injection * 60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi) * double isotope acquisition 5 min after thallium-201 injection * injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection * rest conventional acquisition 20 min later

DRUG

99mTc-Sestamibi

First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first For tomoscintigraphy

DRUG

Thallium-201

Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection) For tomoscintigraphy

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Wassila DJABALLAH, Dr · Service de Médecine Nucléaire, Hôpital de Brabois, 54511 Vandœuvre les Nancy

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02869126 on ClinicalTrials.gov